Illumina, Inc. $ILMN Shares Purchased by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. increased its stake in Illumina, Inc. by 222.9% in Q2, owning 3,823 shares worth $365,000. Other investors also boosted their positions. Illumina's stock opened at $131.39, with a market cap of $20.08 billion. Analysts have mixed ratings, with a consensus price target of $115.00. Illumina reported Q3 earnings of $1.34 per share, beating estimates.

Coldstream Capital Management Inc. raised its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 222.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,823 shares of the life sciences company's stock after acquiring an additional 2,639 shares during the quarter. Coldstream Capital Management Inc.'s holdings in Illumina were worth $365,000 as of its most recent SEC filing.

GRAIL: Biotech Stock Targeting $100B Cancer Market

Other institutional investors and hedge funds also recently bought and sold shares of the company. Rhumbline Advisers boosted its stake in shares of Illumina by 43.6% in the second quarter. Rhumbline Advisers now owns 631,952 shares of the life sciences company's stock valued at $60,294,000 after purchasing an additional 191,911 shares during the period. AlphaCore Capital LLC acquired a new stake in Illumina during the 2nd quarter worth approximately $208,000. Evelyn Partners Investment Management LLP boosted its position in Illumina by 4,927.3% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company's stock valued at $49,000 after buying an additional 542 shares during the period. Franklin Resources Inc. grew its stake in shares of Illumina by 12.1% in the second quarter. Franklin Resources Inc. now owns 52,693 shares of the life sciences company's stock worth $5,027,000 after acquiring an additional 5,707 shares in the last quarter. Finally, MAI Capital Management increased its position in shares of Illumina by 211.5% during the second quarter. MAI Capital Management now owns 785 shares of the life sciences company's stock worth $75,000 after acquiring an additional 533 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Up 1.2%

Shares of Illumina stock opened at $131.39 on Friday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company has a fifty day simple moving average of $107.97 and a 200-day simple moving average of $99.17. The stock has a market cap of $20.08 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 2.34 and a beta of 1.42. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06.

Strategic Buy Lights Up This Biotech Stock: Time to Invest?

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina's quarterly revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on ILMN shares. Canaccord Genuity Group upped their price target on Illumina from $105.00 to $112.00 and gave the stock a "hold" rating in a report on Friday, October 31st. Morgan Stanley raised their target price on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a report on Monday, August 4th. Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a report on Tuesday, September 2nd. Stephens set a $110.00 price objective on shares of Illumina and gave the company an "overweight" rating in a report on Monday, August 4th. Finally, Daiwa Capital Markets cut shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Illumina presently has an average rating of "Hold" and a consensus price target of $115.00.

Palantir Was Left Out of the S&P 500; It Still Looks Like a Buy

Get Our Latest Analysis on ILMN

Insider Transactions at Illumina

In other news, Director Scott Gottlieb purchased 500 shares of the business's stock in a transaction on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.60% of the stock is owned by corporate insiders.

Illumina Company Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Should You Invest $1,000 in Illumina Right Now?

Before you consider Illumina, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.

While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here